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Abstract
Background: Prostate cancer is one of the most common male cancers worldwide. Active Surveillance (AS) has
been developed to allow men with lower risk disease to postpone or avoid the adverse side effects associated with
curative treatments until the disease progresses. Despite the medical benefits of AS, it is reported that living with
untreated cancer can create a significant emotional burden for patients.
Methods/design: The aim of this study is to gain insight into the experiences of men eligible to undergo AS for
favourable-risk PCa.
This study has a mixed-methods sequential explanatory design consisting of two phases: quantitative followed
by qualitative. Phase 1 has a multiple point, prospective, longitudinal exploratory design. Ninety men
diagnosed with favourable-risk prostate cancer will be assessed immediately post-diagnosis (baseline) and
followed over a period of 12 months, in intervals of 3 month. Ninety age-matched men with no cancer
diagnosis will also be recruited using peer nomination and followed up in the same 3 month intervals.
Following completion of Phase 1, 10–15 AS participants who have reported both the best and worst
psychological functioning will be invited to participate in semi-structured qualitative interviews. Phase 2 will
facilitate further exploration of the quantitative results and obtain a richer understanding of participants’
personal interpretations of their illness and psychological wellbeing.
Discussion: To our knowledge, this is the first study to utilise early baseline measures; include a healthy
comparison group; calculate sample size through power calculations; and use a mixed methods approach to
gain a deeper more holistic insight into the experiences of men diagnosed with favourable-risk prostate
cancer.
Keywords: Prostate cancer, Active surveillance, Psychological adjustment, Anxiety, Depression, Uncertainty,
Mixed methods, Quality of life
Background
Prostate cancer (PCa) is one of the most common
male cancers worldwide [1]. This is partially attribut-
able to the increasing use of prostate specific antigen
(PSA) testing which has led to over-diagnosis, and as
a result, possible overtreatment of lower risk PCa [2].
Curative treatments e.g. radical prostatectomy and ra-
diation therapy result in substantial adverse side ef-
fects to the patient in terms of urinary, bowel and
sexual dysfunction. Active surveillance (AS) has been
developed in response to this in order to avoid these
adverse side effects of curative treatments until the
cancer progresses further. This usually consists of
regular PSA tests, Digital Rectal Examinations (DRE)
and annual/biannual biopsies. From a medical per-
spective, the efficacy of AS has been well documented
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[3]. However, the perception of living with untreated
cancer can be an additional emotional burden for AS
patients [4]. In a number of qualitative studies, men
illustrated this burden by describing feelings of being
uncertain, afraid and worried [5], and a perception of
“risking one’s life” by undergoing AS [6].
Previous systematic reviews [7, 8] have reported
that men on AS demonstrate favourable psycho-
logical wellbeing, despite the high quality of the re-
views themselves the methodological limitations of
the included studies suggest the need for further
research. The most pertinent of these limitations
included:
 Late baseline measurement, taken when participants
are already on an AS protocol, reducing the ability
to identify possibly significant differences in the
psychological profile of those selecting AS
compared to those choosing curative treatments,
or to healthy peers.
 Selection of only those who have undergone curative
treatments as comparators, thus allowing for
comparison between the psychological effects of AS
and curative interventions, however this does not
enable measurement of the specific psychological
effects of AS on men that could be obtained
through comparison with their healthy peers.
Comparison between peers with no cancer and men
undergoing AS would facilitate understanding of the
impact of screening, biopsy receipt, diagnosis of
PCa, as well as the natural decline associated with
the ageing process.
 Lack of power calculation, making it difficult to
detect the significance of results;
 Use of uni-methodological approaches, which do
not facilitate the combination of general and in-
depth findings that can be attained by the adoption
of a mixed-methods approach.
Aims and Objectives
The overall aim of the study is to explore the experi-
ences of men diagnosed with favourable risk prostate
cancer. This will be achieved through the following
objectives:
Primary objectives
 To determine the difference in anxiety levels
between men undergoing AS for PCa, men eligible
for AS yet opted for curative treatment, and age-
matched non-cancer men.
 To explore and describe patients’ personal
experiences of AS as a management option for
favourable-risk PCa.
Secondary objectives
 To determine the prevalence of general anxiety, PCa
specific anxiety, depression, uncertainty, and
physical symptoms among men on AS.
 To compare AS patients’ depression scores and
physical symptoms with men receiving curative
treatments despite eligibility for AS, and age-
matched non-cancer men.
 To identify the temporal variability of generic
anxiety, PCa specific anxiety, depression and
uncertainty in men diagnosed with favourable-risk
PCa.
 To identify potential personality and/or socio-
demographic characteristics predictive of patients’
decision to undergo AS over active treatment and
how these characteristics predict resulting psycho-
logical and physical wellbeing.
 To explore potential differences in the experiences
of men who report adverse psychological adjustment
following a period of time on AS differ from those




A mixed-methods sequential explanatory design consist-
ing of two phases: quantitative followed by qualitative
[9], will be utilised in the proposed study. Following col-
lection of quantitative data i.e. Phase 1, the qualitative
component will be emergent from the findings of Phase
1. The results of Phase 2 will aid the interpretation of
Phase 1 by providing a context within which the quanti-
tative data can be understood. This method has been re-
ported to be most appropriate for research which seeks
to investigate relationships or trends in quantitative data
while also seeking to explain the mechanism behind
those trends using qualitative methods [10, 11].
Men with a history of prostate cancer and men in a
similar age bracket with no diagnosis of prostate can-
cer have been consulted in the design of this study,
including questionnaire and information sheet design,
to ensure issues such as language and approach to the re-
search is perceived to be appropriate and acceptable.
Participants
Sample size
A power calculation was conducted using GPower soft-
ware [12]. The sample size was calculated based on
mean score and standard deviation on the State-Trait
Anxiety Inventory short form (STAI-6) [13] in two pop-
ulations; men on active surveillance [14] and men of a
similar age group from the general population [15]. At
0.8 power, p value 0.05, and an effect size of 0.392
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(calculated using the AS and general population data
previously cited), the required sample size is 82 partici-
pants per group, 10 % was added to this to allow for at-
trition, resulting in a final sample size of 90 prostate
cancer patients and 90 non-cancer men.
Prostate cancer patients
Inclusion criteria
– Diagnosed with ‘favourable risk PCa’ i.e. low to
intermediate risk PCa (Gleason score ≤7, PSA
<20 ng/mL, clinical stage T1-T2b) [16]
– Eligible to undergo AS but have not yet made their
treatment decision
– Deemed suitable for participation by the consultant
– Adequate understanding of the English language or
a language that has validated translations of each of
the scales used in the study (Phase 1). Phase 2
requires adequate understanding of English
language.
Exclusion criteria
– Previous cancer diagnosis
– PCa that has been reclassified and is no longer
eligible for AS
– Co-morbidities that would impact psychological
functioning e.g. cognitive impairment




– Aged within 5 years of age of the corresponding AS
patient
– Adequate understanding of the English language or
a language that has validated translations of each of
the scales used in the study
Exclusion criteria
– Informal or formal caregiver of the corresponding
AS patient
– Current or previous cancer diagnosis
– Current or previous psychiatric diagnosis
– Diagnosis that would impact psychological




Patients diagnosed with favourable risk PCa (Gleason
score ≤7, PSA <20 ng/mL and clinical stage T1-T2b)
[16] who are eligible for AS will be recruited from
the Northern Ireland Cancer Centre (NICC) and
Belfast City Hospital (BCH). Potential participants
will be identified at the regional Uro-Oncology
Multi-disciplinary Team (MDT) Meeting by oncology
and urology consultants. Eligible patients who
present for their diagnosis/treatment decision ap-
pointment will be informed of the study by their
consultant and with their permission, details passed
to the research team. Potential participants will be
sent an information pack including a participant
information sheet and consent form, and written in-
formed consent will be obtained prior to participa-
tion. Process consent will be used throughout the
study.
Age-matched non-cancer men
The matched non-cancer men will be recruited using
peer-nomination [17]; each participant that opts for AS
will be asked to nominate a male family member or
friend who meets appropriate inclusion and exclusion
criteria. Peer-nomination primarily matches participants
based on age, however previous studies have demon-
strated that this method of recruitment also matches
participants on other demographic factors e.g. education,
relationship status [18, 19]. Should a participant be un-
able or unwilling to nominate someone, potential partic-
ipants will be approached in the university and via
researchers’ social circle who will then be matched to
the AS patient as closely as possible in terms of their
demographic profile [19].
Upon nomination of a suitable peer, the researcher will
contact those nominated via telephone pending the per-
mission of the potential non-cancer participant. Poten-
tial non-cancer participants will be sent an invitation
pack which will include consent forms, information
sheet and stamped addressed envelope for the return of
consent form and questionnaire.
Phase 1—Quantitative
Outcome measures
Demographic information will include: age; marital
status; relationship status; sexual orientation; education
level; employment status; ethnicity; co-morbidities
(physical or psychological); other major life events in
addition to the PCa diagnosis, sexual activity and
personality as measured by the Eysenck Personality
Questionnaire (EPQ) [20]. To assess psychological and
physical functioning, the Centre for Epidemiologic Stud-
ies Depression Scale (CES-D) [21]; State-Trait Anxiety
Inventory (STAI-6) [11]; Memorial Anxiety Scale for
Prostate Cancer (MAX-PC) [22]; Mishel Uncertainty in
Illness Scale—Community version (MUIS-C) [23]; Deci-
sional Regret Scale [24]; EuroQol (EQ-5D-5 L) [25] and
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a modified version of the Expanded Prostate Cancer
Index Composite (EPIC) [26] will be used.
A number of the scales to be used in the proposed
study (EPQ, STAI-6, CES-D, MAX-PC) are based on
a previous AS study conducted in the Netherlands
[14] and therefore are deemed to be suitable for use
in the target population. In addition we will assess
prostate specific function (EPIC), general quality of
life (EQ-5D-5 L), illness uncertainty (MUIS-C) and
decisional regret (DRS). With the exception of the
Decisional Conflict Scale (DCS), the scales used in
the Dutch study have reported acceptable psychomet-
ric properties [13, 14, 21, 27, 28] and have been used
in both prostate cancer populations and the general
population previously [14, 15]. The additional scales
included in the present study have also demonstrated
adequate psychometric properties in the target popu-
lations [24, 29–35].
Prostate cancer patients (AS and AT)
At baseline, (when participants have not yet decided on
their treatment approach), demographic information,
depression (CES-D), anxiety (STAI-6 and MAX-PC),
prostate symptoms (EPIC) and general physical health
(EQ-5D-5 L) will be assessed. Three months post-
commencement of treatment/AS, patients will be asked
to complete CES-D, STAI-6, MAX-PC, MUIS-C, Deci-
sional Regret Scale, EPIC, EQ-5D-5 L, items assessing
PCa knowledge and involvement of the physician in de-
cision making. The same combination of questionnaires
will be completed in 3-month intervals for up to
12 months with the exception of the involvement of the
physician in decision making, pending continued process
consent (see Fig. 1).
To detect potential selection bias, patients who opt
not to participate and those who choose to drop out of
follow-up will be asked to complete a one-item anxiety
Likert scale (“Please indicate the number that shows
how anxious you feel at the moment.”) [36]. This one-
item scale was chosen due to its high correlation with
the STAI-6 and other anxiety scales [37].
Age-matched non-cancer men
As can be seen in Fig. 1, non-cancer participants will be
assessed in 3 month intervals up to 12 months, coincid-
ing with their corresponding AS patient’s follow-up time,
using CES-D, STAI-6, EPIC and EQ-5D-5 L. At initial
assessment, i.e. T3 months, participants will also be
asked to report demographic information and complete
both the EPQ and PCa knowledge questionnaire. Selec-
tion bias will also be assessed using the one-item anxiety
scale [36].
Phase 2—Qualitative
Following completion of Phase 1, 10–15 of those AS
participants who have reported both the best and worst
psychological functioning will be invited to participate in
face-to-face in-depth semi-structured qualitative inter-
views (Fig. 1). Although participants will have provided
written consent at study inception, potential Phase 2
participants will be informed of what is involved in the
interviews, given an opportunity to ask questions/discuss
any concerns and will be made aware of their right to re-
fuse participation or withdraw at any point without pro-
viding an explanation.
The purpose of Phase 2 is to further explore the quan-
titative results of Phase 1, to gain a richer understanding
of participants own interpretation of their illness and its
impact on their psychological wellbeing [38], be it posi-
tive or negative. A recent systematic literature review
conducted by the research team, along with the outcome
of Phase 1, will be used to frame topics for the semi-
structured interviews [10], however participants will also
be encouraged to discuss issues that they feel are of im-
portance to them. Transcripts of each interview will be
audio recorded, and transcribed verbatim.
Participants will be asked to suggest an interview loca-
tion where they feel most comfortable which may in-
clude their own homes or the designated research room
in the cancer centres. Interviews are expected to last for
approximately 60 min however this is dependent on the
participants’ willingness to talk and the depth they wish
to discuss the topics.
Although interviews will consist of a semi-structured
format, with a range of predetermined topics, partici-
pants will be encouraged to discuss issues of personal
importance that the quantitative phase or the phase 2
topic guide may not have addressed. Participants will be
given the opportunity to articulate their own personal
and unique experiences of PCa and AS. Participants will
be viewed as ‘experiential experts’ while exploring their
interpretations of their experiences of prostate cancer
and active surveillance. Verbal and non-verbal observa-
tions will be recorded immediately post-interview in a
field diary to document subtleties that may not be
picked up via audio recorder e.g. mood, emotion, body
language. This field diary will be used to aid data inter-
pretation and analysis [39].
Participants may struggle to discuss issues, such as
sexual symptoms or psychological distress, with the re-
searcher. To overcome this, the researcher will place
emphasis on developing rapport with the participant,
assuming an open and non-judgemental approach and
ensuring the participant is aware of the strict confidence
within which their information will be kept. Previous re-
search has shown that men with prostate cancer em-
brace the opportunity to discuss personal issues in a
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Fig. 1 Flow diagram illustrating study procedures
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confidential research setting outside of their immediate
social circle and medical team, and are willing to provide
rich data on the topic [40].
Analysis
Phase 1—Quantitative
Data analysis will be performed using the Statistical
Package for the Social Sciences (SPSS) Version 22 for
Windows [41].
Basic data will be collected on all men screened. Care
will be taken to ensure the individual’s anonymity is pro-
tected. The number of men screened, those eligible and
ineligible, those accrued and those not willing to partici-
pate with reasons for ineligibility and non-participation
will be recorded and documented. This data will be exam-
ined and descriptive analysis carried out to identify any
differences between participants and non-participants.
Demographics will be summarised using descriptive
statistics for AS, AT and non-cancer participants. AS
and AT participants’ clinical data will also be analysed
using descriptive statistics.
To detect selection bias, a univariate analysis (t-test)
will be used to compare the difference in the scores of a
one-item anxiety Likert scale [36] of those who agreed
to participate and those who did not agree or withdrew
from the study.
Hierarchical linear modelling (HLM) will be used to
analyse the data collected. Use of this method, presents
an opportunity to explore the differences, as well as the
demographic and clinical determinants, in psychological
wellbeing at a group level (i.e. AS, AT, Non-Ca), and an
individual level. HLM further facilitates the exploration
of temporal variability and determinants of this variabil-
ity and patterns of change across individual patients and
participant groups [42]. In longitudinal study designs, at-
trition and missing data is a concern and can limit the
power and interpretability of the study, HLM addresses
this issue in its ability to create the model in spite of
missing or incomplete data [43].
Due to the increased ability to separate individual and
group level variation using HLM, this approach is in
keeping with the rationale of this study in terms of
maintaining a patient-centred approach [43], therefore
allowing the identification of the wider experience of
men undergoing AS, relative to the other included
groups under study, while also remaining sensitive to
the variation in individual experience of AS and PCa.
Phase 2—Qualitative
Transcriptions of audio-recorded interviews will be ana-
lysed using thematic analysis [44].
Thematic analysis is a “method of identifying, analys-
ing and reporting pattern themes within data” [44]. Ana-
lysis will be performed in three stages: data reduction,
data display and conclusion drawing/verification process
[45]. At each stage, findings will be discussed and veri-
fied by the research team in order to assess accuracy of
the interpretation, promote inter-rater reliability and en-
sure rigour in the qualitative phase of the research [46].
NVivo qualitative data analysis software version 10.0
[47] will be used to aid data management.
Integration of Findings
Findings from qualitative and quantitative phases will be
integrated at the analysis stage. Each phase will be ana-
lysed separately and summarised in a mixed methods
matrix in order to integrate the two sets of results [48].
A mixed methods matrix allows researchers to present a
summary of both quantitative and qualitative data to-
gether, which draws attention to patterns, surprises and
paradoxes in single cases and across the sample as a
whole. This technique is increasingly being utilised in
healthcare research due to the added insight it provides
by analysing data obtained from both methodological
approaches together [48].
Ethical considerations
The recruitment of men at the point where they find out
they have prostate cancer presents a potential ethical
issue relating to their psychological vulnerability at this
time. However, these men will only be approached with
the view to provide them with the study information
pack and to obtain permission to contact them via tele-
phone 7–14 days later in order to discuss the study.
Men will not be asked to provide consent or to complete
the questionnaire at this point.
In terms of recruiting non-cancer participants, it is
possible that participating in this study may motivate
them to attend screening for PCa and potentially be di-
agnosed with PCa. This poses an ethical issue, however
due to the use of peer-nomination as the recruitment
strategy, it is anticipated that this will minimise this
issue due to the control participants’ already heightened
awareness of PCa due to the diagnosis of a close family
member or friend. In any case, should a control partici-
pant receive a diagnosis of PCa during the course of
follow-up, no further data will be collected from them;
data received prior to diagnosis will be retained in the
dataset.
The autonomy of participants is central to this investi-
gation. Participants will be made aware that consent is
fluid and that they have the right to withdraw their con-
sent at any time throughout the study without any nega-
tive impact on their healthcare or management. The
researcher will also adhere to the principle of non-
maleficence, above all cause no harm to participants.
All potential participants will have all of the necessary in-
formation for informed consent and had the opportunity
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to ask questions about the study. Written consent will be
obtained without any coercion of study participants. Confi-
dentiality will be assured and the Caldicott Principles ad-
hered to. Participants will be made aware that any digital
recordings will be deleted following transcription. All infor-
mation pertaining to individuals will be anonymised from
the outset of the study and consent sought for the use of
anonymised quotations from participants.
Data will be protected under the provisions of the
Data Protection Act 1998 [49] – the data will only be
used for the purpose of the study, no participant will be
identifiable in any way and all data will be stored in a
locked container in a locked office. Information stored
electronically will be stored on a password-protected
computer for 3 years in line with university policy.
Should electronic information need to be transferred,
password-protected encrypted pen-drives will be used.
In line with the guidance that normally only a member
of the patient’s existing clinical care team should have ac-
cess to patient records, the consultant/clinical nurse spe-
cialist will identify potential participants. To ensure no
patient is approached unnecessarily, the researcher will be
present at the clinic to clarify any uncertainties (anonym-
ously) with the consultant/clinical nurse specialist.
Dissemination
Following completion of the study, findings will be writ-
ten up for submission to peer-reviewed journals and
conference presentations. Summary of findings will be
prepared for consultants and nurse specialists involved
in the study. A lay summary will also be prepared for
dissemination to study participants.
Discussion
The present study has been designed to capture a base-
line assessment of men’s psychological wellbeing before
they make their treatment decision, therefore conclu-
sions can be made regarding the potential bias in terms
of the type of patient that opt for AS or AT. Due to the
longitudinal nature of the study, the experiences of men
at various points in their first 12 months of the cancer
journey can be better understood, particularly if there
are specific times at which additional support is re-
quired. Comparison with men who have no diagnosis of
cancer and those who opt for AT is a further strength in
terms of placing the data in context to support the ana-
lysis and interpretation of results. Use of a power calcu-
lation in order to determine the appropriate sample size
and inclusion of the one item anxiety question for non-
responders and those who wish to be excluded from
follow-up will increase validity and robustness of the
findings. Finally, the collection of both qualitative and
quantitative data will facilitate a more holistic under-
standing of men’s experiences of favourable-risk PCa.
To our knowledge, this study will be the first to include
an early baseline measurement taken before treatment
modalities have been decided; adopt a control group of
men not diagnosed with cancer; use power calculations to
ascertain required sample size; and combine qualitative
and quantitative methodologies. The purpose of adopting
these innovative methodological strategies is to attain a
more complete picture of these men’s experiences.
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